Brooklyn ImmunoTherapeutics (NYSE:BTX) Earns Hold Rating from Analysts at StockNews.com

StockNews.com assumed coverage on shares of Brooklyn ImmunoTherapeutics (NYSE:BTX) in a research report released on Friday. The brokerage issued a hold rating on the stock.

Brooklyn ImmunoTherapeutics Price Performance

BTX opened at $0.21 on Friday. Brooklyn ImmunoTherapeutics has a 12 month low of $0.17 and a 12 month high of $10.10. The stock has a market capitalization of $12.07 million, a P/E ratio of -0.23 and a beta of 4.61. The business has a 50 day simple moving average of $1.03 and a 200-day simple moving average of $1.56.

Brooklyn ImmunoTherapeutics Company Profile

Eterna Therapeutics, Inc is a clinical stage biopharmaceutical company, which engages in creating transformative regenerative medicine treatments for cancer, blood disorders, and monogenic diseases. It offers IRX-2, a human cell-derived cytokine therapy, studying the safety and efficacy of IRX-2 in patients with head and neck cancer in Phase 2B.